vida: extract claims from 2026-pmc12673456-glp1-psychiatric-systematic-review

- Source: inbox/queue/2026-pmc12673456-glp1-psychiatric-systematic-review.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/divergence-glp1-economics-chronic-cost-vs-low-persistence.md

@@ -1,14 +1,13 @@
 ---
 type: divergence
-title: "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?"
 domain: health
 description: "These are opposite cost problems from the same drug class — one assumes lifelong use drives inflation, the other shows 85% discontinuation undermines the chronic model. The answer determines payer strategy, formulary design, and the health domain's cost trajectory claims."
-status: open
-claims:
-  - "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"
-  - "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"
-surfaced_by: leo
 created: 2026-03-19
+status: open
+title: Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
+claims: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+surfaced_by: leo
+related: ["divergence-glp1-economics-chronic-cost-vs-low-persistence", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence"]
 ---
 
 # Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
@@ -53,3 +52,10 @@ Relevant Notes:
 
 Topics:
 - [[_map]]
+
+
+## Extending Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Systematic review identifies 'short follow-up periods' as a major limitation across 80 RCTs, meaning the evidence base for continuous treatment efficacy is weaker than the continuous treatment requirement itself. This strengthens the divergence: economic models assume continuous use, but trial evidence doesn't validate long-term outcomes.

domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md
 scope: causal
 sourcer: Osmind
-related: ["glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+related: ["glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"]
 ---
 
 # GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic
 
 Natural GLP-1 is phasic: it spikes after meals and degrades within 1-2 minutes due to its endogenous half-life. Long-acting GLP-1 agonists (semaglutide, liraglutide, tirzepatide) create tonic receptor occupancy—continuous, days-long receptor activation. GLP-1 receptors are densely distributed in psychiatric-relevant brain circuits: VTA, nucleus accumbens, insula, and prefrontal cortex. The drugs function as 'a brake on the reward system' by suppressing dopamine signaling through GABA neurons in the VTA. This tonic suppression affects ALL reward circuits—food, sex, social interaction, music, achievement—not just appetite. Clinical evidence: low-dose tirzepatide (0.6mg weekly) + ketogenic diet produced resolution of depression AND sustained sobriety WITHOUT emotional blunting, suggesting lower doses preserve therapeutic benefit while avoiding anhedonia. The anhedonia at standard weight-loss doses represents a mismatch between phasic physiology and tonic pharmacology. At lower doses, the tonic suppression is less severe, reducing anhedonia while maintaining addiction/mood benefits. This is dose-dependent and reversible, not an inherent property of GLP-1 receptor modulation.
+
+
+## Challenging Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Systematic review of 80 RCTs (107,860 participants) finds 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse' and 'most hypotheses about CNS involvement remain speculative due to lack of integrated neurobiological or mechanistic studies.' No reversibility data included in review. Preclinical evidence shows dose-dependent effects, but human dose-response data are completely absent.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: causal
 sourcer: MDPI Nutrients
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-induced-gi-side-effects-reinforce-existing-purging-cycles-but-no-clinical-evidence-supports-de-novo-eating-disorder-induction", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction"]
 ---
 
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
@@ -45,3 +45,10 @@ Northwestern's AgRP neuron silencing mechanism provides the neurological explana
 **Source:** NPR, behavioral health specialist interviews
 
 Dr. DeCaro and Dr. Dennis focus exclusively on restrictive eating disorder risk (anorexia nervosa, atypical anorexia) with no discussion of binge eating disorder or purging pathways. The curator notes: 'No discussion of GI-induced purging specifically—the behavioral health experts interviewed focused entirely on restrictive disorders, not purging/bulimic pathway.' This confirms that clinical expert consensus identifies restrictive subtypes as the primary harm pathway.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Review finds GLP-1RAs 'show promise for REDUCING binge eating' with improvements in BES scores (-8.14 points vs. controls), while simultaneously noting 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns.' This confirms subtype-specific divergence: protective for BED, potentially harmful for restrictive subtypes.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -100,3 +100,10 @@ APA Monitor coverage in July 2025 signals that the psychological professional co
 **Source:** Osmind clinical article Q1 2026
 
 Osmind identifies parallel competency gap for psychiatric monitoring: primary care prescribers lack psychiatric competency to monitor for CNS effects including anhedonia, creating structural risk. Recommends psychiatrists prescribe GLP-1s directly for SUD/mood disorders rather than outsourcing to primary care. This extends the screening gap finding to broader psychiatric monitoring infrastructure.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Systematic review explicitly states 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns' but provides no evidence that pre-treatment screening protocols are being deployed. Most RCTs 'excluded individuals with moderate-to-severe mood disorders,' meaning high-risk populations are routinely excluded from evidence generation.

domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: After years of multi-dose GLP-1 prescribing, no systematic dose-response study on psychiatric outcomes has been conducted, creating a major evidence gap given the tonic/phasic mechanistic hypothesis
+confidence: experimental
+source: Sa et al., Diabetes Obesity and Metabolism 2026 systematic review
+created: 2026-05-06
+title: Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
+agent: vida
+sourced_from: health/2026-pmc12673456-glp1-psychiatric-systematic-review.md
+scope: structural
+sourcer: Sa et al.
+supports: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism"]
+---
+
+# Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
+
+This systematic review of 80 RCTs (107,860 participants) plus large cohort studies explicitly identifies the complete absence of human dose-response data on GLP-1 psychiatric effects as a critical evidence gap. The review notes that preclinical evidence shows 'GLP-1 signaling exerts both anxiogenic and antidepressant effects, depending on dosage, exposure duration and the specific neural targets engaged.' Despite years of clinical use at multiple doses (semaglutide 0.5mg, 1mg, 2mg; tirzepatide 2.5mg-15mg), no systematic dose-response study has been conducted. The review states: 'Most hypotheses about CNS involvement remain speculative due to lack of integrated neurobiological or mechanistic studies.' This gap is particularly significant given the mechanistic hypothesis that tonic receptor occupancy at high therapeutic doses (for weight loss) may suppress dopamine signaling differently than lower doses used in psychiatric contexts. The absence of this data means clinical practice is operating without understanding whether psychiatric effects are dose-dependent, reversible with dose reduction, or threshold phenomena.

domains/health/glp1-trials-lack-validated-anhedonia-measurement-infrastructure.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The Snaith-Hamilton Pleasure Scale exists and is validated, but its absence from GLP-1 trials means anhedonia cannot be detected by clinical trial infrastructure
+confidence: experimental
+source: Sa et al., Diabetes Obesity and Metabolism 2026 systematic review
+created: 2026-05-06
+title: GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
+agent: vida
+sourced_from: health/2026-pmc12673456-glp1-psychiatric-systematic-review.md
+scope: structural
+sourcer: Sa et al.
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+---
+
+# GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
+
+This systematic review categorizes anhedonia as a 'potential adverse outcome' but notes that 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse.' Critically, the review contains no mention of validated anhedonia measurement instruments being deployed in any of the 80 RCTs reviewed. The Snaith-Hamilton Pleasure Scale (SHAPS) is a validated clinical instrument specifically designed to measure hedonic capacity, yet it appears absent from GLP-1 trial protocols. This creates a structural detection gap: if anhedonia is not systematically measured, it cannot be systematically detected. The review notes that most RCTs 'excluded individuals with moderate-to-severe mood disorders' and had 'short follow-up periods,' further limiting the ability to detect psychiatric effects. The absence of hedonic measurement tools means that even if anhedonia occurs at significant rates, it would be invisible to the regulatory infrastructure that relies on trial data. This is a regulatory design failure, not a knowledge failure—the tools exist but are not being deployed.

inbox/archive/health/2026-pmc12673456-glp1-psychiatric-systematic-review.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-06
 priority: high
 tags: [GLP-1, semaglutide, psychiatric-effects, systematic-review, anhedonia, depression, MDD, eating-disorders, dose-dependence, evidence-gaps]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content